Third Rock rolls $47m dice on cancer immunotherapy and Jounce 'dream team'

As one of the founders and the sole funder for Jounce Therapeutics' $47 million Series A venture funding round, Third Rock Ventures has placed a big bet on cancer immunotherapies, but the firm is working with a group of clinicians and researchers hand-picked to ensure that at least some of Jounce's wagers pay off.